好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical and Immunological Features of Inflammatory Myopathy (IM) in Patients with Myasthenia Gravis (MG)
Muscle Disease/Neuromuscular Junction
(-)
037
Authors/Disclosures
No disclosure on file
Kimiaki Utsugisawa, MD, PhD (Hanamaki General Hospital) Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Utsugisawa has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viela Bio. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chugai. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubisi Tanabe pharma. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Utsugisawa has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for argenx. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion phama. Dr. Utsugisawa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Japan Blood Products Organization. Dr. Utsugisawa has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB.
Hiroaki Yoshikawa, MD (Department of Neurology, Kanazawa University) No disclosure on file
Masakatsu Motomura, MD (Nagasaki University) No disclosure on file
Shiro Matsubara, MD, PhD (Matsubara Hospital) No disclosure on file
Nicholas W. Wood (National Hospital for Neuro.) No disclosure on file
Chi-Ying (Roy) Lin, MD, FAAN (Baylor College of Medicine) Dr. Lin has received research support from Texas Alzheimer's Research and Care Consortium (TARCC). Dr. Lin has received research support from CurePSP. Dr. Lin has received research support from Mike Hogg Fund. Dr. Lin has received research support from The Michael J. Fox Foundation Parkinson's Progression Markers Initiative (PPMI). Dr. Lin has a non-compensated relationship as a Secretary with Broadway for Ataxia Foundation (a 501 (c) (3) non-profit organization) that is relevant to AAN interests or activities.
Kazumasa Yokoyama, MD No disclosure on file
Yuriko Nagane, MD, PhD (Hanamaki General Hospital, Neurology Dept) No disclosure on file
Takahiro Maruta No disclosure on file
No disclosure on file
Norihiro Suzuki No disclosure on file